This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| De Novo (FDA process) | |
|---|---|
| Name | De Novo () |
| Caption | Regulatory classification pathway for novel medical devices |
| Type | Regulatory pathway |
| Agency | Food and Drug Administration |
| Jurisdiction | United States |
| Introduced | 1997 |
| Current status | Active |
De Novo (FDA process) The De Novo process is an administrative pathway of the Food and Drug Administration for classification of novel low-to-moderate risk medical devices that lack a legally marketed predicate device. It enables manufacturers to obtain a risk-based classification and marketing authorization when the device is not eligible for a traditional 510(k) submission and does not require a Premarket Approval application. The pathway balances premarket evidence requirements with postmarket controls to protect public health while facilitating medical device innovation.
The pathway was created to address devices deemed novel after a negative determination in a 510(k) review or pursuant to petitions under statutory authorities enacted by the Medical Device Amendments of 1976. The De Novo route results in a new device classification regulation and establishes special controls or general controls applicable to subsequent devices. Key stakeholders in the process include manufacturers, the Center for Devices and Radiological Health, external advisory panels such as the Medical Device Advisory Committee, and interested parties including patient advocacy organizations like PatientsLikeMe and professional societies such as the American Medical Association.
De Novo authority derives from amendments and regulatory implementation tied to statutes such as the Food, Drug, and Cosmetic Act and later legislative changes including the Food and Drug Administration Modernization Act of 1997 and the 21st Century Cures Act. The Food and Drug Administration exercises authority through rulemaking and guidance documents developed by the Office of the Commissioner (FDA) and the Office of Device Evaluation. Judicial decisions from federal courts and interpretive policy from the Department of Health and Human Services have influenced how De Novo petitions are reviewed and the scope of "substantial equivalence" findings that distinguish De Novo from the 510(k) pathway.
A sponsor may seek De Novo classification after a device receives an adverse determination in a 510(k) review or may submit directly under criteria set by the Center for Devices and Radiological Health. The application must describe device design, intended use, technological characteristics, and proposed labeling, and is reviewed under administrative procedures overseen by the Office of Regulatory Affairs and the Office of Combination Products when relevant. Interactions often involve pre-submission meetings with review divisions, and sponsors may engage consultants with expertise from organizations such as Underwriters Laboratories, testing bodies like National Institute of Standards and Technology, and standards-setting entities like International Electrotechnical Commission and International Organization for Standardization.
Evidence expectations combine bench testing, nonclinical studies, and, when necessary, clinical data demonstrating safety and effectiveness relative to identified risks. The review standard applied by the Food and Drug Administration for De Novo is risk-based mitigation through general and special controls rather than the premarket proof threshold applicable to Premarket Approval. Clinical trial designs may be informed by guidance from professional organizations like the American College of Cardiology, ethical review by Institutional Review Board panels, and statistical standards referenced in publications from the National Institutes of Health. Sponsors must also address biocompatibility testing standards promulgated by Food and Drug Administration guidance and standards from ASTM International.
Following authorization, devices classified via De Novo are subject to postmarket surveillance tools administered by the Food and Drug Administration, including Medical Device Reporting, the MedWatch program, and, when warranted, Post-Approval Studies or Section 522 postmarket surveillance orders. The agency may require labeling changes, risk evaluation and mitigation strategies similar to those used by Centers for Medicare & Medicaid Services for coverage decisions, and registries coordinated with academic centers such as Mayo Clinic or Johns Hopkins University to collect real-world evidence. Recalls and corrective actions are coordinated with the Federal Drug Administration’s compliance programs and, when necessary, enforcement actions tied to the Department of Justice.
Unlike the 510(k) pathway, which demonstrates substantial equivalence to a legally marketed predicate device, the De Novo process creates a new classification when no predicate exists. Compared with Premarket Approval, De Novo typically requires lower premarket evidence intensity, focusing on controls proportionate to risk rather than the rigorous clinical trial evidence often expected for PMA. Distinctions also affect reimbursement and coverage interactions with payers such as Centers for Medicare & Medicaid Services and private insurers, and influence litigation dynamics involving plaintiffs' firms and defense counsel in federal courts including the United States Court of Appeals for the Federal Circuit.
Devices authorized via De Novo have included novel software-based diagnostics developed by companies like 23andMe, digital therapeutics aligned with guidance from American Psychiatric Association-linked initiatives, and new classes of implantable devices evaluated in collaboration with institutions such as Cleveland Clinic. De Novo has been credited with lowering barriers for innovative entrants including startups incubated by Y Combinator and venture-backed firms funded by investors like Sequoia Capital, while raising questions addressed by policy analyses from think tanks such as the Brookings Institution and congressional oversight by the House Committee on Energy and Commerce. The pathway continues to shape the medtech landscape by providing a predictable route for novel, low-to-moderate risk technologies to reach patients while enabling the Food and Drug Administration to establish appropriate regulatory controls.
Category:United States medical device regulation